FDA approves first adjuvant treatment for patients with non-small cell lung cancer Today, the U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation. Today's approval of Tagrisso demonstrates how additional research on therapies approved in later stages of cancer can eventually improve treatment options for patients in earlier stages. With this approval, patients may be treated with this targeted therapy in an earlier and potentially more curative stage of non-small cell lung cancer." Richard Pazdur, M.D., Director, FDA's Oncology Center of Excellence and Acting Director, Office of Oncologic Diseases in the FDA's Center for Drug Evaluation and Research